Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

作     者：Vicky Makker 

作者机构：From the Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical Center New York (V.M.) the European Institute of Oncology IRCCS University of Milan-Bicocca Milan (N.C.) Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale Naples (S.P.) and Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred Heart Rome (D.L.) - all in Italy San Carlos University Teaching Hospital (A.C.H.) and Hospital Universitario Ramón y Cajal (E.M.G.) - both in Madrid Yale University School of Medicine New Haven CT (A.D. Santin) Gustave Roussy Cancerology Institute Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens (GINECO) Villejuif (E.C.) and Centre Léon-Bérard University Claude Bernard GINECO Lyon (I.R.-C.) - both in France the University of Texas Southwestern Medical Center Dallas (D.S.M.) Saitama Medical University International Medical Center Hidaka (K.F.) Kurume University School of Medicine Kurume (K.U.) Aichi Cancer Center Hospital Nagoya (J.S.) and National Cancer Center Hospital-Kokuritsu Gan Kenkyu Center Chuo Byoin Tokyo (K.Y.) - all in Japan Royal North Shore Hospital St. Leonards NSW Australia (S.B.-H.) Sheba Medical Center Ramat Gan Israel (R.S.-F.) Asan Medical Center University of Ulsan Seoul South Korea (Y.-M.K.) Ege University Izmir Turkey (U.A.S.) University College London Hospitals NHS Foundation Trust London (M.M.M.) and Eisai Hatfield (A.D. Smith) - both in the United Kingdom and Merck Kenilworth (S.K. S.B. R.J.O.) and Eisai Woodcliff Lake (L.D.) - both in New Jersey. 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2021年第43卷第11期

页      面：1924-1924页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Eisai and Merck Sharp and Dohme 

主　　题：chemotherapy intravenous cancer 

摘      要：Background:Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains ***:In this phase 3 trial,we randomly assigned,in a 1:1 ratio,patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib(20 mg,administered orally once daily)plus pembrolizumab(200 mg,administered intravenously every 3 weeks)or chemotherapy of the treating physician s choice(doxorubicin at 60 mg per square meter of body-surface area,administered intravenously every 3 weeks,or paclitaxel at 80 mg per square meter,administered intravenously weekly[with a cycle of 3 weeks on and 1 week off]).